Psychedelics like psilocybin and LSD have gained enormous attention as potential treatments for depression, PTSD, and addiction, but the push to legalize them carries real risks that deserve serious consideration. The safety data, while often framed optimistically, reveals gaps in knowledge about who these substances can harm, how a commercial market would function, and whether the safeguards built into clinical trials could survive contact with the real world.
Psychiatric Risks for Vulnerable People
One of the strongest arguments against broad legalization centers on the people most likely to be harmed. Clinical trials routinely exclude anyone with a personal or family history of schizophrenia or bipolar disorder, which means the encouraging safety data we see in headlines comes from a pre-screened, lower-risk population. That exclusion exists for good reason: a study of over 16,000 adolescent twins found that psychedelic use was significantly associated with more manic symptoms in individuals carrying higher genetic vulnerability to schizophrenia or bipolar I disorder. In a legalized market, there is no reliable way to screen every consumer for genetic predisposition to these conditions, and many people don’t know their family psychiatric history.
The clinical record includes severe outcomes. In one study of inpatients with treatment-resistant psychotic disorders who received LSD, three participants developed serious complications. One became paranoid after a single dose and attempted suicide three days later, then experienced manic symptoms lasting at least four months. Another developed alternating manic and depressive episodes with psychotic features that also persisted for months. These were supervised clinical settings with medical staff on hand. In a retail or retreat environment, the response capacity would be far more limited.
Lasting Perceptual Disturbances
Hallucinogen Persisting Perception Disorder, or HPPD, is a condition in which visual disturbances from a psychedelic experience continue long after the drug has left the body. People with HPPD may see halos around objects, trailing images, or flickering patterns for weeks, months, or in some cases years. The prevalence is considered low, but it can develop in anyone, even after a single use, and it is more commonly diagnosed in people with a history of psychological issues or substance misuse. The condition remains poorly understood, and its subtypes are still debated within the psychiatric diagnostic system. No reliable treatment exists. Legalization would inevitably expose a much larger population to this risk, including people who would never have sought out psychedelics in an illegal market.
Drug Interactions With Common Medications
Tens of millions of Americans currently take antidepressants, most of which work by increasing serotonin activity in the brain. Psychedelics also act on the serotonin system, and combining the two raises the possibility of serotonin toxicity, a spectrum of reactions that ranges from mild discomfort to a life-threatening emergency. The most severe form, serotonin syndrome, can involve seizures, extreme fever, muscle rigidity, and dangerously unstable vital signs.
The risk level depends on the specific combination. Psychedelics paired with a monoamine oxidase inhibitor (a type found in ayahuasca brews and certain older antidepressants) carry the highest danger. Combinations without MAOIs are generally considered lower risk, but “lower risk” is not “no risk,” and the nuance of which combinations are safe is not something most consumers would navigate accurately on their own. A legalized market would need to account for the fact that the very people most drawn to psychedelics for mental health reasons are the ones most likely to already be on serotonergic medication.
Patient Vulnerability and Therapist Misconduct
Psychedelic experiences involve profound alterations in consciousness. People under the influence often feel deeply emotionally open, highly suggestible, and unable to maintain normal personal boundaries. A systematic review of ethical issues in psychedelic-assisted therapy found that these altered states make patients particularly vulnerable to emotional distress, undue influence, sexual abuse, and various forms of exploitation. The review identified higher risks of relational harm and sexual misconduct compared to standard therapy, with specific concerns around maintaining professional boundaries during sessions that can last six to eight hours.
These are not theoretical worries. Reports of therapist misconduct have already surfaced from underground therapy settings and clinical trials alike. The intimate, emotionally charged nature of the psychedelic experience creates a power dynamic that is difficult to regulate even with strict oversight. Scaling this into a commercial industry, where profit incentives compete with safety protocols, amplifies the problem considerably. Commercial retreat organizations, for example, may be more inclined to accept participants with risky contraindications in order to increase revenue.
The Cost and Access Problem
Legalization advocates often frame psychedelic therapy as a breakthrough for people failed by existing treatments. But the emerging reality of legal access suggests it will be expensive and limited. In Oregon, the first state to legalize psilocybin services, facilitators planned to charge an average of $1,388 per session, with a median of $900. These sessions are not covered by insurance. For a treatment that may require multiple sessions plus preparation and integration appointments, the total cost puts it out of reach for most of the people who need it most.
Training qualified facilitators is also slow and costly. Oregon’s early workforce data shows financial strain among new facilitators due to training expenses, and there is no established pipeline producing enough practitioners to meet potential demand. Legalization without adequate infrastructure risks creating a two-tier system: expensive, supervised experiences for the wealthy, and unsupervised, unregulated use for everyone else.
Emergency Room and Hospital Admissions
Between 2016 and 2023, over 21,700 people aged 16 to 64 had at least one hallucinogen-related emergency department visit or hospital admission in a large insurance database analysis published in JAMA Network Open. The monthly share of hallucinogen-related admissions among all substance-related admissions roughly doubled during that period, rising from 0.59% in January 2016 to 1.18% in January 2021. While these numbers are small relative to alcohol or opioid admissions, they represent real crises for the individuals involved, and the data includes ketamine and esketamine alongside classical psychedelics, making it difficult to isolate the contribution of psilocybin or LSD alone. Broader legalization would likely increase the number of people using these substances, including people using them without medical supervision, without screening, and without the controlled settings that clinical trials depend on.
Cardiovascular Unknowns
Psilocybin and related compounds activate a receptor in the body called 5-HT2B, which is located on heart valves. Chronic activation of this receptor by other drugs has been linked to valvular heart disease, a condition where the heart’s valves thicken and stop functioning properly. This is the same mechanism that led to the withdrawal of the diet drug fenfluramine in the 1990s. Whether the intermittent dosing pattern expected in psychedelic therapy poses the same risk is unknown, but it has raised enough concern that researchers and the FDA have flagged it as an issue requiring careful long-term monitoring. For a substance being proposed for broad public access, this kind of unresolved cardiovascular question is significant.
The Gap Between Trials and Real-World Use
Nearly every positive finding about psychedelics comes from tightly controlled clinical trials. Participants are carefully screened for psychiatric and medical risk factors. Sessions take place in calm, supervised environments with trained professionals present throughout. Integration therapy follows the experience. This is not what legalization produces. Legalization produces a consumer market where individuals self-select, where screening may be cursory or absent, where sessions happen in variable conditions, and where follow-up care is optional.
The safety profile established in clinical research simply does not transfer to a commercial or decriminalized environment. The 2.1% rate of serious adverse events seen among psychiatric inpatients given LSD in older studies, and the 0.5% rate of worsening suicidal ideation among outpatients given psilocybin, occurred under direct medical supervision. Without that supervision, the rate of harm would almost certainly be higher, and the ability to intervene quickly would be lower. The question is not whether psychedelics have therapeutic potential under ideal conditions. It is whether legalization can replicate those conditions at scale, and the evidence so far suggests it cannot.